HanchorBio, Inc. (TWSE: 7827) has entered a strategic research collaboration with a National Taiwan University team participating in the Taiwan Cancer Moonshot Program, creating a new translational research link between patient-derived cancer multi-omics data and the biotechnology company’s clinical-stage immunotherapy pipeline. The collaboration, formalised through a memorandum of understanding between HanchorBio’s Taiwan subsidiary and the team led by Professor Sung-Liang Yu, is intended to investigate biomarkers, treatment-response biology and patient-selection strategies that could support more precise development of HanchorBio therapies.
The agreement is scientifically relevant because HanchorBio is no longer operating purely at the preclinical platform stage. Its lead asset HCB101 is already being studied across multiple cancers, while HCB301 has entered first-in-human development. That means the most valuable outcome from the Taiwan Cancer Moonshot relationship would not simply be another collection of molecular observations, but evidence capable of informing trial design, patient stratification or mechanistic interpretation in active development programmes.
At the same time, the announcement should not be interpreted as evidence that HanchorBio has already identified a validated predictive biomarker for HCB101 or another candidate. The parties described areas they intend to explore, including biomarkers associated with response and resistance, relationships between tumour biology and innate or adaptive immunity, macrophage regulation, T-cell functional states and the integration of patient-derived molecular information into clinical development. No prospectively validated biomarker, companion diagnostic, defined patient-selection algorithm or clinical outcome resulting from the collaboration has yet been disclosed.
Why could Taiwan Cancer Moonshot multi-omics data matter to HanchorBio’s immunotherapy strategy?
The scientific logic centres on a persistent problem in immuno-oncology: biological complexity can make it difficult to predict which patients will respond to a particular immune mechanism. A tumour’s genomic alterations provide only part of the picture. Protein expression, signalling activity, immune-cell composition, stromal biology and other molecular characteristics can materially influence how a cancer behaves and interacts with treatment.
The Taiwan Cancer Moonshot Program provides a potentially useful research environment for investigating those layers. The Academia Sinica-led programme brings together researchers from Academia Sinica, National Taiwan University and clinical institutions and has developed datasets incorporating genomics, proteomics, integrated multi-omics information and clinically annotated patient samples. The programme has also participated in international proteogenomics collaborations involving the United States National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium and the International Cancer Proteogenome Consortium.
That research foundation has produced more than a theoretical infrastructure. A 2025 international lung adenocarcinoma analysis involving National Cancer Institute researchers and the Taiwan Cancer Moonshot team examined hundreds of tumours and matched normal tissues across Asian, North American and Eastern European populations. The work identified molecular features associated with tumour biology and prognosis and illustrated why integrating several biological layers can reveal distinctions that may be missed by genomics alone.
For HanchorBio, the opportunity is to move from broad biological characterisation toward drug-specific translational questions. The collaboration could potentially test whether molecular or immune patterns correlate with response, resistance or durability in therapies designed around macrophage and broader immune modulation. That step is substantially harder than identifying an interesting molecular signature because any candidate biomarker ultimately requires analytical validation, replication and preferably prospective clinical confirmation before it can reliably guide treatment development.
How does the partnership fit with HCB101’s increasingly focused clinical development path?
HCB101 provides the clearest context for understanding why HanchorBio is investing in deeper translational biology. The investigational therapy is an engineered SIRPα-IgG4 Fc fusion protein designed to interfere with the CD47-SIRPα immune checkpoint while limiting red blood cell binding. HanchorBio is developing the molecule as a macrophage-directed combination therapy across selected tumour types rather than relying solely on monotherapy development.
The company’s clinical programme has increasingly concentrated on second-line gastric and gastroesophageal junction cancer as its principal development setting. Following a Type C meeting, HanchorBio reported in June that United States Food and Drug Administration feedback supported continued dose and schedule exploration of HCB101 with ramucirumab and paclitaxel in the ongoing Phase 1b/2a HCB101-201 study, followed by a proposed randomised Phase 2b lead-in and ultimately a confirmatory Phase 3 strategy using overall survival as the primary endpoint. The agency feedback does not constitute approval of the drug or of a future registration application, but it gives the company a more defined framework for further development.
HanchorBio has also reported early activity from other HCB101 cohorts. At the 2026 American Society of Clinical Oncology meeting, the company presented early results from monotherapy and combination studies spanning gastric cancer, colorectal cancer, head and neck squamous cell carcinoma and triple-negative breast cancer. Those results remain derived from early-stage studies and relatively small patient groups, meaning response percentages should not be treated as confirmatory efficacy evidence or directly compared with results from unrelated trials.
A later July update reported that 11 efficacy-evaluable patients across four second-line colorectal cancer combination cohorts included six partial responses and five cases of stable disease as of a July 17 data cutoff. HanchorBio itself acknowledged that the observations were preliminary, came from small nonrandomised cohorts and required additional enrolment and longer follow-up to clarify durability, progression-free survival, safety and the specific contribution made by HCB101 within multidrug regimens.
This is precisely where a stronger biomarker framework could become commercially and clinically relevant. If HanchorBio can identify reproducible biological characteristics associated with response or resistance, future studies could potentially become more informative than broad all-comer expansion cohorts. However, whether the Taiwan Cancer Moonshot collaboration can actually generate such markers remains an open research question.
Could macrophage and T-cell profiling help explain why some tumours respond differently?
HanchorBio’s FBDB platform is designed around the idea that tumour immunity involves several interacting biological systems rather than a single checkpoint. HCB101 concentrates heavily on the macrophage-associated CD47-SIRPα pathway, while HCB301 extends the company’s approach by combining modulation of CD47-SIRPα, PD-L1/PD-1 and TGF-β-related biology within a single investigational fusion protein. HCB301 has reached Phase 1 development in advanced solid tumours.
The Moonshot collaboration therefore has scope to address questions that extend beyond one asset. HanchorBio and Professor Yu’s team specifically plan to examine macrophage-mediated immune regulation alongside T-cell functional states and tumour-intrinsic biology. That could be important if the company wants to understand not merely whether a patient responded but which features of the immune microenvironment may have contributed to that outcome.
Still, associations discovered through multi-omics analysis can be difficult to translate into usable clinical biomarkers. Large datasets can generate numerous correlations, particularly when genomic, proteomic and immune variables are studied simultaneously. A biomarker that appears associated with response in an exploratory dataset may not reproduce in an independent population, and retrospective associations can weaken when tested prospectively.
Consequently, the practical value of this collaboration will depend on the study architecture that follows the memorandum. Particularly important questions include whether analyses are linked to patients receiving defined HanchorBio therapies, whether samples are collected prospectively, whether candidate markers can be measured through clinically practical assays and whether findings can be validated across independent populations.
Why could Asian cancer datasets add another dimension to precision oncology development?
The geographic and demographic composition of the Taiwan Cancer Moonshot datasets could also matter. Precision oncology programmes developed mainly from Western datasets may not fully capture molecular, environmental or epidemiological differences present across Asian populations. The National Cancer Institute has highlighted how the international lung adenocarcinoma project involving Taiwan researchers examined differences associated with population background, smoking history, environmental exposures and sex across geographically diverse cohorts.
That does not mean a biomarker identified in a Taiwanese or East Asian population will automatically translate into a globally useful patient-selection tool. The opposite challenge applies as well: discoveries made within one population must be tested across appropriate external cohorts before broad generalisation.
For a company such as HanchorBio, which is pursuing multinational clinical development, the ideal outcome would therefore be biomarkers that are informative within Asian populations while retaining relevance across broader international trial populations. This becomes particularly important if biomarker findings eventually influence inclusion criteria, stratification variables or regulatory discussions in multiregional studies.
What remains unproven after the HanchorBio and Taiwan Cancer Moonshot agreement?
The memorandum establishes access to complementary scientific capabilities, but it does not by itself establish that HanchorBio’s therapies will become more effective, that clinical trials will succeed or that a biomarker-guided regulatory strategy will emerge. The announcement did not identify a specific biomarker programme already ready for prospective testing, disclose financial terms for the collaboration, or provide a defined timetable for the first translational readout.
It is also notable that the collaboration was described at the pipeline level rather than being formally restricted to HCB101. That gives HanchorBio flexibility to apply emerging biological insights to HCB101, HCB301 or later FBDB-derived candidates, but it also means the immediate clinical deliverable is less defined than it would be in a collaboration built around a specific companion diagnostic or prespecified clinical study.
The next meaningful evidence will therefore come from execution rather than the signing of the memorandum. A scientifically persuasive progression would involve identifying drug-relevant biological hypotheses, testing them against patient samples, reproducing important signals in independent datasets and eventually embedding the strongest candidate biomarkers into prospective clinical development.
HanchorBio already has the unusual advantage of connecting this research effort to therapies that are in human testing, rather than attempting to build a precision-oncology strategy around preclinical assets alone. Its challenge is now to show that the additional molecular resolution supplied by the Taiwan Cancer Moonshot collaboration can produce decisions that materially improve development, whether through better patient selection, stronger mechanistic understanding, more informative trial stratification or clearer interpretation of treatment resistance.
Until those outputs emerge, the collaboration is best viewed as a potentially valuable translational infrastructure investment rather than validation of HanchorBio’s precision immunotherapy thesis. If the programme can eventually connect multi-omics signatures with prospectively reproducible clinical outcomes, however, it could give the company something more consequential than another research partnership: a biological framework for determining where its macrophage-directed and multi-axis immunotherapies have the strongest rationale to advance.